KRAS and cancer: Either the addition of pharmacologic ascorbate or chloroquine can impair KRAS mutation in a dose-dependent manner (see black dots called “in cancer + low dose of ascorbate/chloroquine” and “in cancer + high dose of ascorbate/chloroquine” on Figure 3A,B).